Press & Announcements

News
  • CANTON, Mass. – April 5, 2018
    Former Acelity, J&J Executive Joins Organogenesis as Vice President of Global Medical & Clinical Affairs
    Dr. Shabnam Vaezzadeh Joins Organogenesis Leadership Team in Strategic Medical Direction Role
    Shabnam Vaezzadeh, MD, MPA, formerly of Acelity, KCI, and Johnson & Johnson LifeScan, has joined Organogenesis Inc. as Vice President of Global Medical & Clinical Affairs, the company announced today.
    (Read full version of this press release...)
  • CANTON, Mass. – March 15, 2018
    Organogenesis Announces New PuraPly® Antimicrobial Small Size
    Organogenesis Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets, today announced its PuraPly® Antimicrobial (AM) wound management product is now available in a new, easy-to-use 1.6 cm disc size.
    (Read full version of this press release...)
  • National Diabetes Awareness Month – November 2017
    National Diabetes Awareness Month is an excellent time for people with diabetes – and their loved ones – to learn about good foot care and make it a priority. It could save your life and your limbs. Read our Patient Facts Sheet and stay a step ahead of diabetic foot ulcers!
    (Click here to view the Patient Facts Sheet...)
  • WINSFORD, UK/CANTON, Mass. – October 26, 2017
    Advanced Medical Solutions Group and Organogenesis Inc. Enter into Patent Out-licensing Agreement
    Organogenesis to Obtain Immediate Access to Patent and License in U.S.
    AMS to recognize $2.5 million in 2017; annual royalty on net sales until 2026
    Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced wound care specialist company, and Organogenesis Inc., a commercial leader in regenerative medicine focused on advanced wound care and surgical biologics, today announced the two companies have entered into an out-licensing agreement on a U.S. patent (“Patent”) for a collagen-based wound dressing containing Polyhexamethylene Biguanide (“PHMB”) (“Licensed Product”).
    (Read full version of this press release...)
  • CANTON, Mass. – October 20, 2017
    Organogenesis Highlights Latest Wound Care Research, Launches New Amniotic Wound Care Product Line and New PuraPly™ Antimicrobial Wound Matrix Small Size at SAWC Fall 2017
    For the first time since the recent acquisition of NuTech Medical, Organogenesis Inc. will present its expanded advanced wound care product portfolio at the Symposium on Advanced Wound Care Fall (SAWC Fall) meeting held this week in Las Vegas.
    (Read full version of this press release...)
  • CANTON, Mass. – September 19, 2017
    Organogenesis Names New Chief Commercial Officer and Chief Operating Officer
    Senior Leadership Team Announced as Company Expands Commercial Operations, Product Portfolio
    Organogenesis Inc., a commercial leader in the field of regenerative medicine with a portfolio of advanced and next-generation bioactive and acellular biomaterials products in the advanced wound care and surgical biologics markets, has elevated two industry veterans and longtime company employees, Brian Grow and Patrick Bilbo, to Chief Commercial Officer and Chief Operating Officer, respectively.
    (Read full version of this press release...)
  • CANTON, Mass. – July 27, 2017
    Organogenesis Inc. Sponsors American Podiatric Medical Association Education Programs, Annual Scientific Meeting
    Organogenesis Inc. today announced its 2017 sponsorship of the American Podiatric Medical Association (APMA), including support for three of the APMA’s leading educational programs: The Residency Education Resource Center (REdRC), the Young Physicians’ Institute (YPI) and the Young Physicians’ Practice Management Expo & Coding Seminar. Organogenesis will also sponsor the APMA 2017 Annual Scientific Meeting (The National), taking place this week in Nashville, Tenn.
    (Read full version of this press release...)
  • CANTON, Mass. – July 13, 2017
    PuraPly™ Antimicrobial Named One of Top 10 Innovations in Podiatry
    PuraPly™ Antimicrobial (PuraPly™ AM), an FDA 510(k)-cleared wound management product from Organogenesis Inc., has been named one of the “Top 10 Innovations in Podiatry” by Podiatry Today, an award-winning publication that covers the latest developments in podiatric medicine.
    (Read full version of this press release...)
  • CANTON, Mass. – July 5, 2017
    Organogenesis Inc. Sponsors Wound Healing Exhibition at the International Museum of Surgical Science
    Organogenesis Inc., a global leader in advanced wound care innovation and technologies, announced today it will be a 2017 sponsor of the International Museum of Surgical Science’s exhibition on the history and future of wound healing sciences. Under the direction of lead scientific adviser William J. Ennis, DO, MBA, Section Chief of Wound Healing & Tissue Repair at University of Illinois Health, the exhibit, titled “Wound Healing: Ancient Wisdom, Modern Technology” details the history of wound healing from ancient times to modern day and features various artifacts ranging from classical medical materials to modern-day biotechnology innovations.
    (Read full version of this press release...)
  • CANTON, Mass. – June 26, 2017
    Organogenesis Shares Best Practices for Rapid Sterility Detection Techniques for Cell-Based Therapies at Future Cell Therapy Commercialization Summit
    SVP of Quality Systems Discusses Novel Sterility Test Method When Manufacturing Allogeneic Cell-Based Therapy Products
    Cell therapy scientists, researchers and product developers will learn about advanced rapid sterility detection techniques employed by Organogenesis Inc. at the Future Cell Therapy Commercialization Summit held June 26-28 in Boston, Massachusetts. The summit brings together leading industrial cell therapy experts to discover, debate and discuss how to successfully commercialize personalized cell therapies.
    (Read full version of this press release...)
  • CANTON, Mass. – May 22, 2017
    Organogenesis Closes on a $20 Million Facility from Eastward Capital Partners
    Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, today closed a $20 million financing facility with Eastward Capital Partners, a leading provider of venture debt and equity financing to technology companies.
    (Read full version of this press release...)
  • CANTON, Mass. – April 10, 2017 /PRNewswire/
    Organogenesis Secures $25M Credit Facility from Silicon Valley Bank
    Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, has entered into a revolving line of credit agreement with Silicon Valley Bank (SVB), the bank of the world's most innovative companies and their investors. This agreement provides $25 million of new capital to the company to be used for working capital and general corporate purposes.
    (Read full version of this press release...)
  • CANTON, Mass. – April 6, 2017
    Organogenesis Shares Successes and Best Practices for Cell-Based Product Manufacturing at the 6th Stem Cell Product Development and Commercialization Conference
    Company’s Senior Vice President of Quality Speaks at Expert Panel On Manufacturing and Scalable Processes
    Stem cell scientists, researchers and product developers will learn more about Organogenesis’ state-of-the art manufacturing process and successful commercial-scale production of FDA-approved wound healing therapies at the 6th Stem Cell Product Development and Commercialization Conference held April 6-7 in Boston, Massachusetts. The conference highlights cutting-edge developments in all areas of stem cell research, including the biology, medicine, applications and regulation of stem cells.
    (Read full version of this press release...)
  • Canton, Mass / San Diego, CA – April 6, 2017
    Organogenesis Celebrates Product Acquisitions; Highlights New Research at SAWC Spring 2017
    This week, during the 30th Annual Symposium on Advanced Wound Care Spring|Wound Healing Society meeting (SAWC Spring|WHS), Organogenesis will celebrate company milestones – including the recent acquisition of NuTech Medical and the three-year anniversary of the Dermagraft® acquisition – and highlight new products and research at the nation’s largest interdisciplinary wound care forum, held April 5-9 in San Diego.
    (Read full version of this press release...)
  • Canton, MA / Birmingham, AL – March 28, 2017
    Organogenesis Inc. Announces Acquisition of NuTech Medical
    Acquisition Creates Regenerative Medicine Powerhouse in Wound Care, Orthopedic and Surgical Markets
    Organogenesis Inc., a commercial leader in the field of regenerative medicine, is expanding beyond wound care with the acquisition of NuTech Medical. The newly-combined company will offer a portfolio of advanced and next generation products for the wound care and surgical biologics markets.
    (Read full version of this press release...)
  • CANTON, Mass. – March 27, 2017
    Organogenesis Announces Launch of PuraPly™ Antimicrobial Clinical Research Program
    Multi-site, prospective studies, and a patient registry, commence across the country with a total of 440 patients to be enrolled
    Organogenesis Inc., a global leader in advanced wound care innovations and technologies, today announced the launch of a PuraPly™ Antimicrobial (PuraPly™ AM) clinical research program which will comprise multiple studies and a nationwide patient registry.
    (Read full version of this press release...)
  • CANTON, Mass. – January 4, 2017
    Apligraf® is First Wound Healing Therapy to Demonstrate Significant Change in Chronic Wound’s Genomic Profile
    - New Research Evaluating Apligraf’s® Role in Converting Chronic Wound Environment into Acute Healing Profile Published in Science Translational Medicine -
    (Read full version of this press release...)
  • CANTON, Mass. – December 14, 2016
    PuraPly™ and PuraPly Antimicrobial (AM)™ Receive Permanent Q-Code, Expanding Medicare Coverage After January 1 to Include Treatment in Private Physician Office Setting
    PuraPly Products Retain Pass-Through Reimbursement Status Throughout 2017
    Organogenesis Inc., a global leader in advanced wound care innovations and technologies, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned permanent Q-codes for its PuraPly™ and PuraPly Antimicrobial (AM)™ wound management products.
    (Read full version of this press release...)
  • CANTON, Mass. – November 21, 2016
    Congressman Joe Kennedy III Tours Massachusetts-Based Biotech Firm Organogenesis Inc.
    -Global Leader in Advanced Wound Care Showcases Industry-Leading Products, R&D Laboratories, Manufacturing Facilities-
    U.S. Representative Joe Kennedy III (MA-4) today visited the Canton, Mass. headquarters of Organogenesis Inc., a global leader in advanced wound care innovation and technologies, to tour its research and development labs and manufacturing facilities, meet with employees, and learn about biotechnology solutions that are improving the lives of millions of Americans battling non-healing, chronic wounds like diabetic foot ulcers (DFUs).
    (Read full version of this press release...)
  • CANTON, Mass. and LAS VEGAS, Nev. ‐ Oct. 6, 2016
    Organogenesis’ Advanced Wound Care Portfolio Highlighted at SAWC Fall 2016
    This week, new data and information featuring Organogenesis’ FDA-approved bioengineered cell-based products Apligraf® and Dermagraft®, and wound management products PuraPly™ and PuraPly Antimicrobial (AM)™ will be presented at the Fall Symposium on Advanced Wound Care (SAWC), the nation’s largest interdisciplinary wound care forum, held October 7-9, 2016 in Las Vegas.
    (Read full version of this press release...)
  • Canton, Mass – September 19, 2016
    Organogenesis Announces New Chief Financial Officer
    Tim Cunningham has been appointed Chief Financial Officer of Organogenesis Inc., President and CEO Gary S. Gillheeney, Sr. announced today.
    (Read full version of this press release...)
  • Canton, Mass – September 12, 2016
    Nation's Leading Developer of Advanced Wound Care Technologies Urges FDA to Finalize Regulatory Guidance to Ensure Safety and Efficacy of Section 361 HCT/Ps
    Organogenesis Inc., a global leader in FDA-approved and FDA-cleared advanced wound care innovation and technologies, today urged the U.S. Food and Drug Administration (FDA) to finalize two draft guidance documents that would clarify the existing regulatory criteria for determining if products qualify for regulation solely as Section 361 Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps) – and in doing so, bring needed regulatory oversight to the wound care industry.
    ( Read full version of this press release...)
  • Canton, Mass – August 26, 2016
    Advanced Wound Care Products PuraPly™ and PuraPly Antimicrobial™ Now Available for Medicare Reimbursement in 10 Additional States
    -Decision by National Government Services to Retire Policy on Application of Cellular or Tissue Based Products Effective September 1, 2016 -
    Organogenesis, a global leader in advanced wound care innovations and technologies, today announced that its PuraPly™ and PuraPly Antimicrobial (AM)™ wound management products are now eligible for Medicare coverage and reimbursement in 10 additional states, providing coverage for an additional 7.5 million Medicare beneficiaries, following the decision by National Government Services (NGS) to retire its local coverage determination (LCD) for cellular and tissue-based products (CTPs) effective September 1, 2016.
    ( Read full version of this press release...)
  • Canton, Mass – May 18, 2016
    New Research Highlights Ability of PuraPly™ and PuraPly Antimicrobial (AM)™ to Manage Bioburden and Support Healing Across Variety of Wound Types
    Three new research abstracts presented at the recent 2016 Symposium on Advanced Wound Care (SAWC) highlight the role of PuraPly™ and PuraPly Antimicrobial (AM)™ – two new FDA-cleared collagen matrix products from Organogenesis Inc. – in managing bioburden and supporting wound healing across a variety of wound types.
    ( Read full version of this press release...)
  • Canton, Mass – May 11, 2016
    Award-Winning Research from the University of Miami Evaluates Apligraf’s® Role in Reversing a Chronic Wound Environment
    Award-winning research from a multidisciplinary team at the University of Miami provides new insight on what happens to a patient’s genomic profile when Apligraf®, an FDA-approved, bioengineered living cell-based therapy from Organogenesis Inc., is applied to a chronic venous leg ulcer (VLU), when compared to conventional therapy alone. The analysis found that Apligraf altered specific molecular and cellular responses in the wound environment, reversing the chronic wound profile to resemble more of an acute wound profile.
    ( Read full version of this press release...)
  • Canton, Mass / San Diego, CA – April 14, 2016
    Organogenesis Secures $30 Million in Financing to Fund Aggressive Expansion of Commercial Operations and Product Portfolio
    Organogenesis Inc. - a global leader in advanced wound care innovation and technologies – has raised approximately $30 million in capital from existing investors to support a significant expansion of the company’s commercial operations, sales force, PuraPly product line, and new product development in the wound care and surgical fields.
    ( Read full version of this press release...)
  • Canton, Mass / Atlanta, GA – April 14, 2016
    Organogenesis’ Expanding Wound Care Portfolio Featured in Eight New Presentations This Week at SAWC/WHS Spring 2016
    This week, new data featuring Organogenesis’ bioengineered cell-based wound healing products Apligraf® and Dermagraft®, and the wound management products PuraPly™ and PuraPly Antimicrobial (AM)™, will be presented at the Symposium on Advanced Wound Care (SAWC) / Wound Healing Society (WHS) Spring Meeting, the leading national wound healing conference being held in Atlanta, Georgia.
    ( Read full version of this press release...)
  • Canton, Mass / Manassas, Virg. – November 24, 2015
    Department of Veterans Affairs Expert Holds Diabetes Awareness Month Educational Webinar for Veterans on Diabetic Foot Care and Limb Loss Prevention
    As part of Diabetes Awareness Month, the Amputee Coalition and Organogenesis Inc. convened an educational webinar for U.S. Veterans, their families, caregivers, and clinicians on preventing limb loss for patients battling diabetes. The webinar comes at a time when nearly half of the U.S. population is diabetic or pre-diabetic and the rate of diabetic patients at the Veterans Health Administration is around 25 percent.
    ( Read full version of this press release...)
  • Canton, Mass / Reinach, Switzerland – November 2, 2015
    Apligraf® Wound Healing Technology Becomes First Transplant Product to Receive Marketing Approval in Switzerland
    Organogenesis Inc. today announced that its Apligraf® wound-healing technology has become the first transplant product in Switzerland to receive marketing authorization from Swissmedic for the treatment of venous leg ulcers (VLU) and diabetic foot ulcers (DFU). In Switzerland, the classification of "transplant products" includes cell therapies such as Apligraf.
    ( Read full version of this press release...)
  • Canton, Mass – October 8, 2015
    Comparative Effectiveness Analyses Report Faster Healing Times, Improved Probability of Chronic Wound Closure with Apligraf® and Dermagraft®
    Three new real-world, comparative effectiveness analyses reporting the clinical outcomes of Apligraf® for the treatment of hard-to-heal venous leg ulcers (VLUs), and Dermagraft® for the treatment of chronic diabetic foot ulcers (DFUs), were recently presented at the Fall Symposium for Advanced Wound Care (SAWC) annual medical meeting in Las Vegas, Nev. Apligraf® and Dermagraft® are the only living cell-based products in the "skin substitute" category to have received FDA approval for chronic wound healing. They are both manufactured by Organogenesis Inc., a global leader in regenerative medicine for wound healing.
    ( Read full version of this press release...)
  • Canton, Mass/Las Vegas, Nev. – September 24, 2015
    Organogenesis to Feature Comparative Effectiveness Analyses and New Products at SAWC Fall 2015
    This week Organogenesis Inc. will highlight its growing portfolio of advanced wound care products and present the results of real-world, comparative effectiveness analyses, demonstrating the effectiveness of its Apligraf® and Dermagraft® living cell-based therapies, compared to Epifix, Primatrix and Theraskin, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, being held September 26-28, 2015 in Las Vegas, Nev.
    ( Read full version of this press release...)
  • ORLANDO, FL. – July 29, 2015
    At APMA: "Shifting the Antimicrobial Paradigm" non-CECH Presentation Examines PuraPly AM
    ( Read full version...)
  • ORLANDO, FL. – July 22, 2015
    Organogenesis Launches New PuraPly™ Products at the APMA 2015 Annual Scientific Meeting
    This week at the American Podiatric Medical Association (APMA) Annual Scientific Meeting, Organogenesis Inc. will launch its new PuraPly™ wound management products. This includes the launch of PuraPly Antimicrobial (PuraPly AM), the first Food and Drug Administration (FDA)-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent.
    ( Read full version of this press release...)
  • CANTON, MASS. – June 22, 2015
    Landmark New Data: Apligraf® Closes Significantly More Diabetic Foot Ulcers in Half the Time When Compared to Epifix
    A new real-world comparative effectiveness analysis, published online this week in the peer-reviewed journal Wound Repair & Regeneration, reported that Apligraf® has demonstrated improved outcomes over Epifix by a wide margin. The large-scale analysis, the first of its kind, examined healing rates of patients with diabetic foot ulcers (DFUs) who were treated either with Organogenesis' Apligraf® or with Epifix, made by MiMedx Group, Inc.
    ( Read full version of this press release...)
  • CANTON, MASS. – March 26, 2015
    Journal of Medical Economics Publishes Findings from Groundbreaking Research Demonstrating the Health Economic Benefits of Apligraf® and Dermagraft®
    Organogenesis Inc., a world leading regenerative medicine company, announced publication of groundbreaking new data demonstrating significantly improved outcomes and economic benefits of both Apligraf® and Dermagraft® in the treatment of diabetic foot ulcers (DFUs) in the peer-reviewed Journal of Medical Economics.
    ( Read full version of this press release...)